Can Tirzepatide Cause Hair Thinning?
Based on current clinical guidelines and available evidence, hair thinning is not a recognized or documented adverse effect of tirzepatide therapy.
Evidence Review
The comprehensive guideline documents and clinical trial data for tirzepatide do not identify hair thinning or alopecia as an adverse event associated with this medication 1, 2.
Documented Adverse Effects
The most common adverse events associated with tirzepatide are:
- Gastrointestinal effects (most frequent): diarrhea (12%-21%), nausea (13%-18%), and delayed gastric emptying as a class effect 1, 3
- Hypoglycemia risk: minimal when used as monotherapy or with metformin, but increases substantially when combined with insulin or sulfonylureas 1, 2
- Serious adverse events: occur less frequently with tirzepatide compared to insulin (RR 0.79), with no increased risk of major adverse cardiovascular events 1
Clinical Trial Safety Data
In the SURPASS clinical trial program, which included extensive safety monitoring across multiple phase 3 trials, hair thinning was not reported among the treatment-emergent adverse events 4, 3, 5. The real-world evaluation of 612 patients over a median of 10.4 months similarly did not identify hair loss as a concern 5.
Important Considerations
If a patient on tirzepatide reports hair thinning, investigate alternative causes:
- Rapid weight loss: Tirzepatide produces substantial weight loss (mean reduction of 7.3-8.8 kg), and rapid weight loss from any cause can trigger telogen effluvium 1, 5
- Nutritional deficiencies: Secondary to gastrointestinal side effects or inadequate intake during weight loss 6
- Uncontrolled diabetes: Hair loss can occur with poorly controlled type 2 diabetes itself 4
- Concurrent medications: Review other medications that may cause alopecia 1
The hair thinning is more likely related to the metabolic changes from weight loss rather than a direct drug effect of tirzepatide 1, 5.